Oncosec Medical Incorporated's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Oncosec Medical Incorporated (ONCS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Oncosec Medical Incorporated's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Oncosec Medical Incorporated | - | - | - | Yes |
| Competitors combined (126) | ||||
| High-Confidence Competitors (7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ONCS Stock Performance relative to its Competitors
ONCS Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Erasca Inc | 282.9% | Outperformed |
| 3 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 4 | Alpha Tau Medical Ltd | 282.9% | Outperformed |
| 5 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Oncosec Medical Incorporated's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Oncosec Medical Incorporated
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Oncosec Medical Incorporated |
0.72 | - |
 Bristol myers Squibb Company |
128,928.40 | 50,033.00 |
 Madrigal Pharmaceuticals Inc |
13,113.46 | 1,427.94 |
 Tg Therapeutics Inc |
10,106.93 | 799.54 |
 Nuvalent Inc |
9,751.98 | 4.23 |
 Protagonist Therapeutics inc |
9,675.42 | 281.99 |
| SUBTOTAL | 270,950.45 | 59,969.02 |
Sign in to see all competitors of Oncosec Medical Incorporated.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Oncosec Medical Incorporated versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Oncosec Medical Incorporated's Competitors Named by the Company
Competitive relationships identified from Oncosec Medical Incorporated reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Iovance Biotherapeutics inc | Company report | 85% |
| Bristol Myers-Squibb | Company report | 85% |
| Syndax | Company report | 85% |
| Idera Pharmaceuticals | Company report | 85% |
| Checkmate | Company report | 85% |
| Immunomedics | Company report | 85% |
| Dynavax Technologies | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Werewolf Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Oncosec Medical Incorporated's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Oncosec Medical Incorporated's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Protagonist Therapeutics inc | Single reportable segment 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
| Xencor Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Oncosec Medical Incorporated.
Oncosec Medical Incorporated's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Oncosec Medical Incorporated | 1 | - | -1,959,058 |
| Bristol myers Squibb Company | 128,928 | 1,539,477 | 284,338 |
| Madrigal Pharmaceuticals Inc | 13,113 | 1,560,590 | -169,905 |
| Tg Therapeutics Inc | 10,107 | 2,003,850 | 1,106,491 |
| Nuvalent Inc | 9,752 | 18,566 | -1,974,009 |
| Protagonist Therapeutics inc | 9,675 | 2,136,303 | 616,273 |
| PEERS TOTAL | 270,950 | 1,245,825 | 76,522 |
Sign in to see all peers for Oncosec Medical Incorporated.
Oncosec Medical Incorporated's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Bristol myers Squibb Company | United States 69.43 % |
| Iovance Biotherapeutics inc | US 98.66 % |
| Hutchmed china Limited | CN 74.28 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.73 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Oncosec Medical Incorporated.
Oncosec Medical Incorporated's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.5x | - |
| EV / EBITDA | - | 15.4x | - |
| P/B | 1.3x | 4.2x | -2.9x |
| Return on Equity | -868.37 % | industry aggregate | -886.57 % |
| Return on Invested Capital | -213.20 % | -9.78 % (avg) | -203.42 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Oncosec Medical Incorporated's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Return on Invested Capital | -58.08 % | -33.70 % | -111.22 % | -76.49 % | -56.58 % | -213.20 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Oncosec Medical Incorporated's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 886.6 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (59.20 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-11.9% annualized).
Methodology: see Methodology: SWOT Analysis.
Oncosec Medical Incorporated's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Oncosec Medical Incorporated | 1.62 | 2.02 | 0.16 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Madrigal Pharmaceuticals Inc | 0.83 | 3.39 | 0.60 |
| Tg Therapeutics Inc | 1.58 | 4.52 | 0.81 |
| Nuvalent Inc | 1.98 | 13.90 | - |
| Protagonist Therapeutics inc | 5.28 | 15.94 | - |
Sign in to see all peers for Oncosec Medical Incorporated.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Oncosec Medical Incorporated's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Oncosec Medical Incorporated | Q4 2022 | - | - |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | +50.1 % | - |
| Tg Therapeutics Inc | Q2 2026 | +70.3 % | -72.4 % |
| Nuvalent Inc | Q1 2026 | - | - |
| Protagonist Therapeutics inc | Q2 2026 | +3,749.2 % | - |
| PEERS TOTAL | +15.8 % | - |
Sign in to see all peers for Oncosec Medical Incorporated.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Oncosec Medical Incorporated's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Oncosec Medical Incorporated | Q4 2022 | - | -93.5 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | - | +1.8 % |
| Tg Therapeutics Inc | Q2 2026 | +117.5 % | +597.6 % |
| Nuvalent Inc | Q1 2026 | - | - |
| Protagonist Therapeutics inc | Q2 2026 | - | -79.3 % |
Sign in to see all peers for Oncosec Medical Incorporated.
Oncosec Medical Incorporated's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Oncosec Medical Incorporated | - | - | - |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Tg Therapeutics Inc | 33.59% | 39.26% | 72.30% |
| Nuvalent Inc | - | - | - |
| Protagonist Therapeutics inc | 11.02% | 11.66% | 11.80% |
Sign in to see all peers for Oncosec Medical Incorporated.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Oncosec Medical Incorporated's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Oncosec Medical Incorporated | - | - |
| Bristol myers Squibb Company | 13.92 | 2.58 |
| Madrigal Pharmaceuticals Inc | - | 9.18 |
| Tg Therapeutics Inc | 23.42 | 12.64 |
| Nuvalent Inc | - | 2,303.80 |
| Protagonist Therapeutics inc | 133.59 | 34.31 |
| PEERS AVERAGE | 74.15 | 4.52 |
Sign in to see all peers for Oncosec Medical Incorporated.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.